Receptor tyrosine kinases in normal and malignant haematopoiesis

Blood Reviews

Volumn 17, Issue 4, 2003, Pages 241-248

  Reilly, John T ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

AML; c Kit; FLT3; Mutations; Pathogenesis; Prognosis; RTKs

Indexed keywords

CYTOKINE; FIBROBLAST GROWTH FACTOR RECEPTOR; FLT3 LIGAND; GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; CHRONIC LEUKEMIA; ENZYME BINDING; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HUMAN; LEUKEMOGENESIS; LIGAND BINDING; MAST CELL LEUKEMIA; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW;

EID: 0242386261     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(03)00024-9     Document Type: Review

References (100)

1. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411: 355-365.
2. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298: 1912-1934.
3. Robinson DR, Wu Y-M, Lin S-F. The protein tyrosine family of the human genome. Oncogene 2000; 19: 5548-5557.
4. Gupta R, Knight CL, Bain BJ. Receptor tyrosine kinase mutations in myeloid neoplasms. Br J Haematol 2002; 117: 489-508.
5. Zumkeller W, Burdach S. The insulin-like growth factor system in normal and malignant hematopoietic cells. Blood 2002; 94: 3653-3657.
6. Correa PN, Eskinazi D, Axelrad AA. Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-I in vitro: studies in an improved serum-free medium. Blood 1994; 83: 99-112.
7. Wu HK, Wekdsberg R, Minden MD, Squire JA. Loss of imprinting of human insulin-like growth factor II gene, IGF2, in acute myeloid leukaemia. Biochem Biophys Res Commun 1997; 231: 466-472.
8. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A. Human protooncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987; 6: 3341-3351.
9. Rosnet O, Schiff C, Pébusque M-J, Marchetto S, Tonnelle C, Toiron Y, Birg F, Birnbaum D. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood 1993; 82: 1110-1119.
10. Claesson-Welsh L, Eriksson A, Westermark B, Heldin C-H. cDNA cloning and expression of the human A-type platelet-derived growth factor (PDGF) receptor establishes structural similarity to the B-type PDGF receptor. Proc Natl Acad Sci USA 1989; 86: 4917-4921.
11. Yarden Y, Escobedo JA, Kuang W-J, Yang-Feng TL, Daniel TO, Tremble PM, Chen EY, Ando ME, Harkins RN, Francke U, Fried VA, Ullrich A, Williams LT. Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature 1986; 323: 226-232.
12. Coussens L, Van Beveren C, Smith D, Chen E, Mitchell RL, Isacke CM, Verma IM, Ullrich A. Structural alteration of viral homologue of receptor proto-oncogene fms at C terminus. Nature 1986; 320: 277-280.
13. Yang M, Khachigian LM, Hicks C, Chesterman CN, Chong BH. Identification of PDGF receptors on human megakaryocytes and megakaryocytic cell lines. Thromb Haemost 1997; 78: 892-896.
14. Besmer P, Murphy JE, George PC, Qui F, Bergold PJ, Ledermann L, Synder HW, Brodeur D, Zuckermann EE, Hardy WD. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase family. Nature 1986; 320: 415-421.
15. Tsai M, Takeishi T, Thompson H, Langley KE, Zsebo KM, Metcalfe DD, Geissler EN, Galli SJ. Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand, stem cell factor. Proc Natl Acad Sci USA 1991; 88: 6382-6386.
16. Huizinga JD, Thuneberg L, Kluppel M, Malsz J, Mikkelsen HB, Bernstein A. W/kit gene requirement for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 1995; 373: 347-349.
17. Simmons PJ, Aylett GW, Niutta S, To LB, Juttner LB, Ashman LK. c-kit is expressed by primitive human hematopoietic cells that give rise to colony-forming cells in stroma-dependent or cytokine-supplemented culture. Exp Hematol 1994; 22: 157-165.
18. Linnekin D. Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol 1999; 31: 1053-1074.
19. Longley BJ, Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu SZ, Heitjan D, Ma Y. Activating and dominant inactivating c-kit catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999; 96: 1609-1614.
20. Tian Q, Frierson HF, Krystal GW, Moskaluk CA. Activating c-kit mutations in human germ cell tumors. Am J Pathol 1999; 154: 1643-1647.
21. Hirota S, Isozaki K, Moriyama Y, Hasimoto K, Nishida T, Ishigura S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad TG, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y. Gain-of-function mutations of human gastrointestinal stromal tumors. Science 1998; 279: 577-580.
22. Furitsu T, Tsuiimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y, Matsuzawa Y, Kitamura Y, Kanakura Y. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993; 92: 1736-1744.
23. Tsujimura T, Furitsu T, Morimoto M, Isozaki K, Nomura S, Matsuzawa Y, Kitamura Y, Kanakura Y. Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation. Blood 1994; 83: 2619-2626.
24. Tsujimura T, Furitsu T, Morimoto M, Kanayama Y, Nomura S, Matsuzawa Y, Kitamura Y, Kanakura Y. Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3. Int Arch Allergy Immunol 1995; 106: 377-385.
25. Buttner C, Henz BM, Welker P, Sepp NT, Grabbe J. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behaviour. J Invest Dermatol 1998; 111: 1227-1231.
26. Ikeda H, Kanakura Y, Tamaki T, Kuriu A, Kitayama H, Ishikawa J, Kanayama Y, Yonzawa T, Tarui S, Griffin J. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukaemia cells. Blood 1991; 78: 2962-2968.
27. Broudy VC, Smith FO, Lin N, Zsebo KM, Egrie J, Berstein ID. Blast from patients with acute myelogenous leukaemia express functional receptors for stem cell factor. Blood 1992; 80: 60-67.
28. Beghini A, Peterlongo P, Ripamonti CB, Larizza L, Cairoli R, Morra E, Mecucci C. C-kit mutations in core binding factor leukemias. Blood 2000; 95: 726-727.
29. Gari M, Goodeve A, Wilson G, Winship P, Langabeer S, Linch D, Vandenberghe E, Peake I, Reilly J. c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol 1999; 105: 894-900.
30. Cairoli R, Grillo G, Beghini A, Tedeschi A, Ripamonti CB, Larizza L, Morra E. C-kit point mutations in core binding factor leukemias: correlation with with blood cell count and the white blood cell index. Leukemia 2003; 17: 471-472.
31. Care RS, Valk PJM, Goodeve AC, Abu-Duhier FM, Geertsma-Kleinekoort WMC, Wilson GA, Gari MA, Peake IR, Lowenberg B, Reilly JT. Incidence and prognosis of c-kit and flt3 mutations in core binding factor (CBF) acute myeloid leukaemia. Br J Haematol 2003; [in press].
32. Reilly JT. FLT3 and its role in the pathogenesis of acute myeloid leukaemia. Leuk Lymph 2003; 44: 1-7.
33. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, Walker H, Wheatley K, Bowen DT, Burnett AK, Goldstone AH, Linch DC. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752-1759.
34. Preudhomme C, Sagot C, Boissel N, Cayuela J-M, Tigaud I, de Botton S, Thomas X, Raffoux E, Lamandin C, Castaigne S, Fenaux P, Dombret H. Favourable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 2002; 100: 2717-2723.
35. Fenski R, Flesch K, Serve S, Mizuki M, Oelmann E, Kratz-Albers K, Kienast J, Leo R, Schwartz S, Berdel WE, Serve H. Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. Br J Haematol 2000; 108: 322-330.
36. Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, Reilly JT. Identification of novel FLT3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol 2001; 113: 983-988.
37. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R, Naoe T. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001; 97: 2434-2439.
38. Mizuki M, Schwäble J, Steur C, Choudhary C, Agrawal S, Sargin B, Steffen B, Matsumura I, Kanakura Y, Böhmer FD, Müller-Tidow C, Berdel WE, Serve H. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood 2003; 101: 3164-3173.
39. Waterfield MD, Scrace GT, Whittle N, Stroobant P, Johnsson A, Wasteson A, Westermark B, Heldin CH, Huang JS, Deuel TF. Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus. Nature 1983; 304: 35-39.
40. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukaemia with t(5;12) chromosomal translocation. Cell 1994; 77: 307-316.
41. Steer EJ, Cross NCP. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor beta. Acta Haematol 2002; 107: 113-122.
42. Baxter EJ, Kulkarni S, Vizmanos JL, Jaju R, Martinelli G, Testoni N, Hughes G, Salamanchuk Z, Calasanz MJ, Lahortiga I, Pocock CF, Dang R, Fidler C, Wainscoat JS, Boultwood J, Cross NC. Novel translocations that disrupt platelet-derived growth factor receptor beta (PDGFRβ) gene in BCR-ABL-negative chronic myeloproliferative disorders. Br J Haematol 2003; 120: 251-256.
43. Baxter EJ, Hochhaus A, Bolufer P, Reiter A, Fernandez JM, Senent L, Cervera J, Moscardo F, Sanz MA, Cross NC. The t(4;22)(q12;11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRα. Hum Mol Genet 2002; 11: 1391-1397.
44. Macdonald D, Aguiar RCT, Mason PJ, Goldman JM, Cross NCP. A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review. Leukemia 1995; 9: 1628-1630.
45. Inhorn RC, Aster JC, Roach SA, Slapak CA, Soiffer R, Tantravahi R, Stone RM. A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathological entity. Blood 1995; 85: 1881-1887.
46. Xiao S, Nalbolu SR, Aster JC, Ma J, Abruzzo L, Jaffe ES, Stone R, Weissman SM, Hudson TJ, Fletcher JA. FRGF 1 is fused with a novel zinc-finger gene, ZNF 198, inthe t(8;13) leukemia/lymphoma syndrome. Nat Genet 1998; 18: 84-87.
47. Popovici C, Zhang B, Grégoire M-J, Jonveaux P, Lafage-Pochitaloff M, Birnbaum D, Pébusque M-J. The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. Blood 1999; 93: 1381-1389.
48. Chaffanet M, Popovici C, Leroux D, Jacrot M, Adelaide J, Dastugue N, Gregoire MJ, Hagemeijer A, Lafage-Pochitaloff M, Birnbaum D, Pebusque MJ. t(6;8), t(8;9) and t(8;13) translocations associated with stem cell myeloproliferative disorders have close or identical breakpoints in chromosomal region 8p11-12. Oncogene 1998; 16: 945-949.
49. Intini D, Baldini L, Fabris S, Lombardi L, Ciceri G, Maiolo AT, Neri A. Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). Br J Haematol 2001; 114: 362-364.
50. Chesi M, Brents LA, Ely SA, Bais C, Robbiani DF, Mesri EA, Kuehl WM, Bergsagel PL. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001; 97: 729-736.
51. Li Z, Zhu YX, Plowright EE, Bergsagel PL, Chesi M, Patterson B, Hawley TS, Stewart AK. The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood 2001; 97: 2413-2419.
52. Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ, Belch AR, Pilarski LM. In multiple myeloma t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003; 101: 1520-1529.
53. Veikkola T, Karkkainen M, Claesson-Welsh I, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factors. Cancer Res 2000; 60: 203-212.
54. Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition, Trends Pharmacol Sci 2001; 22: 201-207.
55. Katoh O, Tauchi H, Kawaishi K, Kimura A, Satow Y. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res 1995; 55: 5687-5692.
56. Ratajczak MZ, Ratajczak J, Machalinski B, Majka M, Marlicz W, Carter A, Pietrzkowski Z, Gewirtz AM. Role of vascular endothelial growth factor (VEGF) and placenta-derived growth factor (PIGF) in regulating human haemopoietic cell growth. Br J Haematol 1998; 103: 969-979.
57. Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M, Hossfeld DK. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukaemia. Blood 1997; 89: 1870-1875.
58. Aguago A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M, Giles F, Estrov Z, Barlogie B, Albitar M. Cellular vascular endothelial growth factor as a predictor of outcome in patients with acute myeloid leukaemia. Blood 1999; 94: 3717-3721.
59. Verstovek S, Estey E, Manshouri T, Giles FJ, Cortes J, Beran M, Rogers A, Keating M, Kantarjian H, Albitar M. Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelosplastic syndrome. Br J Haematol 2002; 118: 151-156.
60. Saaristo A, Karkkainen MJ, Alitalo K. Insights into the molecular pathogenesis and targeted treatment of lymphedema. Ann N Y Acad Sci 2002; 979: 94-110.
61. Labouyrie E, Dubus P, Groppi A, Mahon FX, Ferrer J, Parrens M, Reiffers J, de Mascarel A, Merlio JP. Expression of neurotrophins and their receptors in human bone marrow. Am J Path 1999; 154: 405-415.
62. Reuther GW, Lambert QT, Caligiuri MA, Der CJ. Identification and characterization of an activating TrkA deletion mutation in acute leukaemia. Mol Cell Biol 2000; 20: 8655-8666.
63. Verstovsek S, Estey E, Manshouri T, Keating M, Kantarjian H, Giles FJ, Albitar M. High expression of the receptor tyrosine kinase Tie-1 in acute myeloid leukemia and myelodysplastic syndrome. Leuk Lymph 2001; 42: 511-516.
64. Muller A, Lange K, Gaiser T, Hofmann M, Bartels H, Feller AC, Merz H. Expression of angiopoietin-1 and its receptor TEK in hematopoietic cells from patients with myeloid leukaemia. Leuk Res 2002; 26: 163-168.
65. Vikkula M, Boon LM, Carraway KL, Calvert JT, Diamonti AJ, Goumnerov B, Pasyk KA, Marchuk DA, Warman ML, Cantley LC, Mulliken JB, Olsen BR. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 1996; 87: 1181-1190.
66. Gattei V, Celetti A, Cerrato A, Degan M, De Iuliis A, Rossi FM, Chiappetta G, Consales C, Improta S, Zagonei V, Aldinucci D, Agosti V, Santoro M, Vecchio G, Pinto A, Grieco M. Expression of the RET receptor tyrosine kinase and GDNFR-α in normal and leukemic human hematopoietic cells and stromal cells of the bone marrow microenvironment. Blood 1997; 89: 2925-2937.
67. Nakayama S, Iida K, Tsuzuki T, Iwashita T, Murakami H, Asai N, Iwata Y, Ichihara M, Ito S, Kawai K, Asai M, Kurokawa K, Takahashi M. Implications of expression of GDNF/Ret signalling components in differentiation of bone marrow haemopoietic cells. Br J Haematol 1999; 105: 50-57.
68. Gilliland DG. Hematologic malignancies. Curr Opin Hematol 2001; 8: 189-191.
69. Rhoades KL, Hetherington CJ, Harakawa N, Yergeau DA, Zhou L, Liu LQ, Little MT, Tenen DG, Zhang DE. Analysis of the role of AML-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood 2000; 96: 2108-2115.
70. Yuan Y, Zhou L, Miyamoto T, Iwasaki H, Harakawa N, Hetherington CJ, Burel SA, Lagasse E, Weissman IL, Akashi K, Zhang DE. AMLI-ETO expression is directly involved in the development of acute myeloid leukaemia in the presence of additional mutations. Proc Natl Acad Sci USA 2001; 98: 10398-10403.
71. Higuchi M, O'Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR. Expression of a conditional AMLI-ETO oncogene bypass embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 2002; 1: 63-74.
72. Castilla LH, Garrett L, Adya N, Orlie D, Dutra A, Anderson S, Owens J, Eckhaus M, Bodine D, Liu PP. The fusion gene Cbfb-MYH 11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukemia. Nat Genet 1999; 23: 144-146.
73. Mueller BU, Pabst T, Osato M, Asou N, Johansen LM, Minden MD, Behre G, Hiddermann W, Ito Y, Tenen DG. Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood 2002; 100: 998-1007.
74. Preudhomme C, Sagot C, Boissel N, Cayuela J-M, Tigaud I, de Botton S, Thomas X, Raffoux E, Lamandin C, Castaigne S, Fenaux P, Dombret H. Favourable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukaemia: a study from the Acute Leukaemia French Association (ALFA). Blood 2002; 100: 2717-2723.
75. Kelly LM, Liu Q, Kutok JL, Williams IR, Boulton C, Gilliland DG. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 2002; 99: 310-318.
76. Kelly LM, Kutok JL, Williams IR, Boulton CL, Amaral SM, Curley DP, Ley TJ, Gilliland DG. PML/RARα and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci USA 2002; 99: 8283-8288.
77. Grisolano JL, O'Neal J, Tomasson MH. An activated tyrosine kinase, TEL-PDGFRB, cooperates with AMLI-ETO to induce acute myeloid leukemia in mice. Blood 2002; 100: 31a.
78. Mulloy JC, Cammenga J, MacKenzie KL, Berguido FJ, Moore MA, Nimer SD. The AMLI-ETO fusion gene promotes the expansion of human hematopoietic stem cells. Blood 2002; 99: 15-23.
79. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine inhibitor for chronic myelogenous leukaemia. J Clin Invest 2000; 105: 3-7.
80. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lynden NB. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmol Exp Therap 2000; 295: 139-145.
81. Frost MJ, Ferrao PT, Hughes TP, Ashman LK. Juxtamembrane mutant V560G kit is more sensitive to Inatinib (STI571) compared to wild-type c-kit whereas the kinase domain mutant D816V kit is resistant. Mol Cancer Therap 2002; 1: 1115-1124.
82. Ueda S, Ikeda H, Mizuki M, Ishiko J, Matsumura I, Tanaka H, Shibayama H, Sugahara H, Takai E, Zhang X, Machii T, Kanakura Y. Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AGI296. Int J Hematol 2002; 76: 427-435.
83. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA, Demetri GD. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001; 20: 5054-5058.
84. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schltheis B, Cross NC, Goldman JM. Response to imatinib mesylate in patients with chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347: 481-487.
85. Kindler T, Breitenbuecher F, Marx A, Hess G, Gschaidmeier H, Gamm H, Kirkpatrick CJ, Huber C, Fischer T. Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML. Blood 2003; 101: 2960-2962.
86. Levis M, Allebach J, Tse KF, Zheng R, Baldwin BR, Smith BD, Jones-Bolin S, Ruggeri B, Dionne C, Small D. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukaemia cells in vitro and in vivo. Blood 2002; 99: 3885-3891.
87. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM. SUI 1248 is anovel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597-3605.
88. Verstovek S, Estey E, Manshouri T, Giles FJ, Cortes J, Beran M, Rogers A, Keating M, Kantarjian H, Albitar M. Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol 2002;118:151-156.
89. Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, Wu Y, Chadburn A, Hyjek E, Gill M, Hicklin DJ, Witte L, Moore MA, Rafii S. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000; 106: 511-521.
90. Yamada K, Ariyoshi K, Onishi M, Miyajima A, Hayakawa F, Towatari M, Saito H, Oka Y, Asano S, Nosaka T, Kitamura T. Constitutively active STAT5A and STAT5B in vitro and in vivo: mutation of STAT5 is not a frequent cause of leukemogenesis. Int J Hematol 2000; 71: 46-54.
91. Yi TL, Cleveland JL, Ihle JN. Protein tyrosine phosphatase containing SH2 domains: characterization, preferential expression in hematopoietic cells, and localization to human chromosome 12p12-p13. Mol Cell Biol 1992; 12: 836-846.
92. Chen H, Chang S, trub T, Neel. Regulation of colony-stimulating factor 1 receptor signaling by the SH2 domain-containing tyrosine phosphatase SHPTPI. Mol Cell Biol 1996; 16: 3685-3697.
93. Paulson R, Vesely S, Siminovitch K, Bernstein A. Signalling by the W/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phosphatase shp 1. Nat Genet 1996; 13: 309-315.
94. Zhang Q, Raghunatyh PN, Vonderheid E, Odum N, Wasik MA. Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the Shp-1 promoter. Am J Pathol 2000; 157: 1137-1146.
95. Oka T, Ouchida M, Koyama M, Ogama Y, Takada S, Nakatani Y, Tanaka T, Yoshino T, Hayashi K, Ohara N, Kondo E, Takahashi K, Tsuchiyama J, Tanimoto M, Shimizu K, Akagi T. gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res 2002; 62: 6390-6394.
96. Piao X, Paulson R, van der Geer P, Pawson T, Bernstein A. Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. Proc Natl Acad Sci USA 1996; 93: 14665-14669.
97. Chen P, Allebach J, Small D. Expression of FLT3/ITD mutations suppresses SHP-1. Blood 2002; 100: 85a.
98. Birkenkamp KU, Geugien M, Lemmink HH, Kruijer W, Vellenga E. Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia 2001; 15: 1923-1931.
99. Helgason CD, Damen JE, Rosten P, Grewal R, Sorensen P, Chappel SM, Borowski A, Jirik F, Krystal G, Humphries RK. Targeted disruption of SHIP leads to hematopoietic perturbations, lung pathology, and a shortened life span. Genes Dev 1998; 12: 1610-1620.
100. Robertson SC, Tynan JA, Donoghue DJ. RTK mutations and human syndromes: when good receptors turn bad. Trends Genet 2000; 16: 265-271.